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Abstract: We aimed to determine whether increased levels of asymmetric dimethylarginine (ADMA) directly cause hepatic deterioration
and whether it is decreased by ascorbic acid (AA) as an antioxidant. The study included three groups: Control (n = 10), ADMA (n =
10), and ADMA + AA (n = 10). ADMA was administered at 2 mg kg–1 day–1 and AA was given at 50 mg kg–1 day–1 for 10 days. Serum
aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase, and alkaline phosphatase activities
were analyzed. Histomorphological evaluation of the liver was performed based on the Ishak scoring system. When compared with the
control, ALT and ALP levels of the ADMA group were significantly higher (P = 0.006 and P = 0.041, respectively). When compared
with the control, interface hepatitis, confluent necrosis, focal necrosis, histological activity index, severity of hepatitis, and portal
inflammation were significantly higher in the group administered ADMA. The mentioned biochemical/histopathological parameters
were lower in the ADMA + AA group when compared with the ADMA group even if no significant difference was encountered (P >
0.05). The results indicate that ADMA is a factor in the formation of liver injury. Insufficient recovery in biochemical/histopathological
parameters when AA was given make us consider that different factors other than prooxidant factors are effective in the formation of
liver injury.
Key words: Asymmetric dimethylarginine, ascorbic acid, Ishak score, alanine aminotransferase, alkaline phosphatase

1. Introduction
Asymmetric dimethylarginine (ADMA) is a methylated
arginine derivative. The first stage in the synthesis of ADMA
is transfer of the methyl from S-adenosyl methionine
(SAM) to the arginine residues in the proteins mediated by
the protein arginine methyl transferase (PRMT1) enzyme.
In the second stage, free ADMA forms after proteolytic
breakdown (Paik and Kim, 1968; Tran et al., 2003; Vallance
and Leiper, 2004; Zakrzewicz and Eickelberg, 2009).
ADMA decreases intracellular nitric oxide (NO) level by
inhibiting nitric oxide synthase (NOS) and also blocking
intracellular penetration of L-arginine, from which NO
is synthesized. Endothelial nitric oxide synthase (eNOS)
and neuronal nitric oxide synthase (nNOS) are the NOS
species that are predominantly inhibited by ADMA.
* Correspondence: okuyucuali@hotmail.com
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Inducible nitric oxide synthase (iNOS) is inhibited at
lower levels (Forstermann et al., 1991; Leiper and Vallance,
1999; Ueda et al., 2003).
An adult subject produces daily 300 µmol (60 mg) of
ADMA (Bode-Boger et al., 2007). The liver and kidneys are
the most important organs in the synthesis and elimination
of ADMA (Kimoto et al., 1993, 1995; Wilcken et al., 2007).
Nijveldt et al. showed a hepatic uptake of ADMA in an
amount of 0.89 nmol 100 g body weight–1 min–1. The liver
eliminates ADMA at rates 700-fold higher than plasma
(Nijveldt et al., 2003a). The liver metabolizes ADMA
particularly by dimethylarginine dimethylaminohydrolase
1 (DDAH1). Beside this, ADMA may also be drained
through the bile duct (Ferrigno et al., 2014) and broken
down to α-keto-d-(N,N-dimethylguanidino)valeric acid
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by alanine glyoxylate aminotransferase 2 (Vallance and
Leiper, 2004; Rodionov et al., 2010).
Changes in DDAH enzymatic activity due to reactive
oxygen species (ROS), inflammatory mediators, ADMA
itself with excessively increased levels, and nitrosative
stress lead to pathophysiological changes in the body
tissues by causing increased hepatic and plasma levels
of ADMA (Leiper et al., 2002; Sydow and Munzel, 2003;
Lee et al., 2005; Nakagami et al., 2009; Nakamura et al.,
2009). The reduction in DDAH1 activity is the main cause
of the elevation in the hepatic levels of ADMA (Jacobi et
al., 2005; Mookerjee et al., 2015). Inflammatory mediators
also contribute to elevated levels of ADMA by activating
PRMT (Sydow and Munzel, 2003; Lee et al., 2005).
Increased levels of ADMA lead to vasoconstriction,
platelet aggregation, cell adhesion to the endothelium,
increased vascular leakage, and increased vascular smooth
muscle cell proliferation (Jeremy et al., 1999; Cerwinka
et al., 2002). ADMA alters the body’s response against
inflammation by causing changes in the inflammatory
mediators (Avci et al., 2015). On the other hand, ADMA
causes increased levels of malondialdehyde (MDA) as
one of the oxidative stress indicators, whereas it results in
reduced activities of antioxidant enzymes such as catalase,
superoxide dismutase (SOD), and glutathione peroxidase
(GSH-Px) (Alaçam et al., 2013). All these effects of ADMA
on NO synthesis, oxidative stress, and the inflammatory
process cause deterioration at the tissue level, primarily
endothelial dysfunction (Iwakiri et al., 2008; Okuyucu et
al., 2015).
ADMA, symmetric dimethylarginine (SDMA), and
L-arginine compete to be carried by cationic amino
acid transporters (CATs) on the cell membrane. When
compared with tissues such as heart, kidney, and lung,
higher rates of CAT expression and uptake of ADMA,
primarily CAT-2A and CAT-2B, are found in the liver
(Forstermann et al., 1991; Hattori et al., 1999; Ferrigno
et al., 2015). Increased ADMA causes a reduction in
levels of intracellular L-arginine by blocking transport of
L-arginine through membranes. The reduction in the level
of L-arginine causes formation of uncoupled eNOS that
shows oxidase activity. Uncoupled eNOS causes formation
of oxygen radicals by reacting with molecular oxygen
instead of arginine (Sydow and Munzel, 2003). Therefore,
increased ADMA causes tissue deterioration by a different
mechanism.
It is found in the literature that the ADMA/DDAH/NO
pathway is considered responsible in the pathophysiology
of many diseases (Sheen et al., 2014). This pathway is
also blamed for the pathophysiology of hepatic diseases.
ADMA levels increase in liver cirrhosis (Lluch et al., 2004),
alcoholic hepatitis (Mookerjee et al., 2007b), and acute liver
failure (ALF) (Mookerjee et al., 2007a). Increased portal
pressure observed with alcoholic hepatitis is associated

with increased levels of ADMA (Mookerjee et al., 2007b).
Some changes occur in the pathway of ADMA/DDAH
also in the case of hepatic ischemia/reperfusion (IR). In
the early period of reperfusion (1 h), DDAH1 mRNA and
protein expressions show a reduction, whereas ADMA
levels increase (Ferrigno et al., 2014). Increased ADMA
under conditions of IR changes the balance between NO
and endothelin and thereby causes vasoconstriction,
which may lead to hepatic deterioration (Laleman et al.,
2005).
Increased ADMA is noticed in the pathophysiology of
many diseases in the literature. However, it is controversial
whether increased levels of ADMA is the reason or the
consequence. In this study, we have aimed to determine
whether increased levels of ADMA directly cause hepatic
deterioration and whether it is decreased by ascorbic acid
as an antioxidant. For this purpose, ADMA was given to
rats and subsequently deterioration and restoration were
examined histopathologically and biochemically.
2. Materials and methods
The required approval was received from the local
ethics committee of Ondokuz Mayıs University. The
experimental animals used in the study were purchased
from the Ondokuz Mayıs University Laboratory Animals
Research and Application Center. Maintenance of the rats,
administration of ADMA and ascorbic acid, euthanasia of
the rats, sample collection, and obtaining of serum samples
were all performed at the same center.
2.1. Experimental animals
Thirty Sprague Dawley rats were used in this study. Body
weights of the rats ranged between 250 and 300 g. The
rats were allowed to receive feed ad libitum prior to and
during the experiment protocols. The rats were kept at a
12-h light/dark cycle. The temperature of the animal barn
was 22 ± 1 °C.
2.2. Study groups
The study included three groups with 10 rats in each group:
1) Control group (n = 10): Administered only 0.2 mL of
0.9% NaCl intraperitoneally (i.p.).
2) ADMA group (n = 10): Administered 2 mg kg–1 day–1
ADMA i.p. (Cat. No. D4268, Sigma-Aldrich, USA)
(Alaçam et al., 2013).
3) ADMA + ascorbic acid (AA) group (n = 10): 2 mg
kg–1 day–1 ADMA i.p. and 50 mg kg–1 day–1 ascorbic
acid (Cat. No. 100468, Merck Millipore, Germany) via
gavage (Donpunha et al., 2011; Nagda and Bhatt, 2011;
Alaçam et al., 2013).
ADMA was dissolved in sterile 0.9% NaCl and each rat
was given 0.2 mL. Ascorbic acid was dissolved in sterile
distilled water and each rat was given 0.5 mL. Both ADMA
and ascorbic acid were given together to the rats for 10
days.
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2.3. Sample collection
After administration of ADMA and ascorbic acid for
10 days, the rats were fasted for one night and sample
collection of blood and liver tissues was initiated. At the
first stage, anesthesia was induced using 100 mg kg–1
ketamine hydrochloride and 10 mg kg–1 xylazine. Blood
samples of rats were obtained by cardiac puncture under
anesthesia and taken into tubes without an anticoagulant;
subsequently, the rats were decapitated. The abdominal
region was opened by incision, and liver tissue samples
were taken and kept in 10% buffered neutral formalin
solution for 24 h.
Blood samples taken into Eppendorf tubes were
centrifuged at 3000 × g for 10 min and the obtained serum
samples were put into Eppendorf tubes to be stored –80
°C.
2.4. Biochemical analyses
After administration of ADMA and AA for 10 days, the
liver enzyme levels were evaluated. Before biochemical
analyses were performed, serum samples were kept at 4 °C
for one night to dissolve slowly. The samples were vortexed.
Serum aspartate aminotransferase (AST), alanine
aminotransferase (ALT), gamma-glutamyl transferase
(GGT), and alkaline phosphatase (ALP) enzyme activities
were tested spectrophotometrically with an autoanalyzer
(Architect c16000, Abbott Laboratories, USA). Enzyme
activities were expressed as U L–1.
2.5. Histopathological examination
After administration of ADMA and AA for 10 days, the
liver histopathology were evaluated. After fixation, all
the samples were divided into slices approximately 0.2
cm thick perpendicular to the long axis of the liver. Two
slices were obtained from each liver and all the cases were
sampled separately. Following the routine procedure,
tissues were blocked in the paraffin. Three sections of 4 µm
in thickness were obtained from each block. Each section
was treated with hematoxylin and eosin (H&E), trichrome,
and reticulin stains. Histomorphological evaluation was
performed based on the Ishak scoring system (Ishak et
al., 1995) (Table 1). Histological activity index (grade) and
fibrosis assessment (stage) were determined separately for
each case. Histological activity index was graded between
0 and 18. Scores of 1 to 3, 4 to 8, 9 to 12, and 13 to 18
were accepted to reveal minimal, mild, moderate, and
severe degrees of hepatitis, respectively. Minimal, mild,
moderate, and severe degrees of hepatitis were expressed
as “1”, “2”, “3”, and “4”, respectively. Fibrosis assessment
(stage) was evaluated separately.
2.6. Statistical analyses
In comparisons between more than two groups, the groups
with normal distribution were tested by one-way ANOVA.
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Significant differences were tested by Tukey HSD test from
the multiple comparison tests. The Kruskal–Wallis H test
was used in comparison of the groups without normal
distribution. Multiple comparisons were performed using
the Bonferroni-corrected Nemenyi test. The correlations
between variables were inspected by Spearman’s rho. P <
0.05 was accepted as statistically significant. The analyses
were performed using SPSS 21.0 (IBM SPSS Statistics,
version 21.0, Armonk, NY, USA; Ondokuz Mayıs
University Network License).
3. Results
3.1. Biochemical analyses
No significant difference was found between groups in
terms of AST and GGT levels (P = 0.107 and P = 0.317,
respectively). Although there was no significant difference,
AST and GGT levels increased in the groups administered
ADMA, whereas AST and GGT levels decreased in the
groups administered ascorbic acid (Table 2).
When compared with the control group, ALT levels
of the ADMA group were significantly higher (P =
0.006). A reduction was observed when ascorbic acid was
administered, even though this reduction was insignificant
(P > 0.05) (Table 2).
When compared with the control group, ALP levels
of the ADMA group were significantly higher (P =
0.041). A reduction was observed when ascorbic acid was
administered, even though this reduction was insignificant
(P > 0.05) (Table 2).
3.2. Histopathological examination
Interface hepatitis was significantly higher in the group
administered ADMA (P = 0.040), whereas, the ADMA
+ AA group revealed significant reduction only when
compared with the group administered ADMA (P = 0.040)
(Table 3; Figures 1 and Figure 2).
When compared with the control group, confluent
necrosis, focal necrosis, and histological activity index
were found significantly higher in the group administered
ADMA (P = 0.001). When ascorbic acid was administered,
a reduction was monitored, even if this reduction was
insignificant (P > 0.05) (Table 3; Figures 1 and 2).
Portal inflammation was found higher in the group
administered ADMA when compared with the control
group (P = 0.030). It was found lower in the ADMA + AA
group when compared with the ADMA group, even if no
significant difference was encountered (P > 0.05) (Table 3;
Figures 1 and 2).
Severity of hepatitis was found significantly higher in
the group administered ADMA when compared with the
control group (P = 0.003). A reduction was observed in
the ADMA + AA group when compared with the group
administered only ADMA, even though this difference
was insignificant (P > 0.05) (Table 3; Figure 1).
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Table 1. Ishak fibrosis scoring system used in histomorphological evaluation (Ishak et al., 1995).
Score
A. Periportal or periseptal interface hepatitis (piecemeal necrosis)
Absent

0

Mild (focal, few portal areas)

1

Mild/moderate (focal, most portal areas)

2

Moderate (continuous around <50% of tracts or septa)

3

Severe (continuous around >50% of tracts or septa)

4

B. Confluent necrosis
Absent

0

Focal confluent necrosis

1

Centrilobular necrosis in some areas

2

Centrilobular necrosis in most areas

3

Centrilobular necrosis + occasional portal–central (P-C) bridging

4

Centrilobular necrosis + multiple P-C bridging

5

Panlobular or multilobular necrosis

6

C. Focal (spotty) lytic necrosis, apoptosis, and focal inflammation
Absent

0

One focus or less per 10× objective

1

One to four foci per 10× objective

2

Five to 10 foci per 10× objective

3

More than 10 foci per 10× objective

4

D. Portal inflammation
None

0

Mild, some or all portal areas

1

Moderate, some or all portal areas

2

Moderate/marked, all portal areas

3

Marked, all portal areas

4

Maximum possible score for grading

18

No significant difference was encountered between the
groups when compared with respect to fibrosis (P = 0.342)
(Table 3).
When the ADMA-administered group was compared to
the control group, histopathological parameters including
interface hepatitis, confluent necrosis, focal necrosis,
histological activity index, and portal inflammation were
significantly higher in the ADMA group than the control
group.

4. Discussion
In this study, liver injury was induced by ADMA in
rats. The injury was showed by using biochemical and
histopathological parameters. Ascorbic acid restored the
injury, but this was not sufficient.
NO is a molecule that is synthesized from L-arginine
mediated by NOS and has important functions in many
pathophysiological events. There are mainly three kinds of
NOS that mediate NO synthesis: endothelial NOS (eNOS,
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Table 2. AST, ALT, ALP, and GGT levels after 10 days of ADMA and AA administration. It is clearly seen that
they were increased in the ADMA-administrated group.
Groups

Control
(mean ± SD)

ADMA
(mean ± SD)

ADMA + AA
(mean ± SD)

P-value

AST (U L–1)

66.60 ± 17.44

85.80 ± 17.24

74.70 ± 23.34

0.107

ALT (U L–1)

27.20 ± 8.84

42.30 ± 12.36

33.70 ± 6.55

0.006*

ALP (U L )

49.30 ± 19.00

91.70 ± 56.99

65.20 ± 14.13

0.041*

GGT (U L )

0.40 ± 0.70

6.90 ± 9.78

2.70 ± 5.27

0.317

–1

–1

*Obtained by comparison between the control and ADMA groups. AST: aspartate aminotransferase; ALT:
alanine aminotransferase; ALP: alkaline phosphatase; GGT: gamma-glutamyl transferase; ADMA: asymmetric
dimethylarginine; AA: ascorbic acid.

Figure 1. Light micrographs of the histological view of the liver after 10 days of ADMA and AA administration. A) There is mildmoderate inflammation in all portal areas in the group administered ADMA. Piecemeal necrosis in a portal area (thin arrow) and
confluent necrosis in the parenchyma (thick arrow) are noteworthy (H&E 100×). B) Although the basic histological structure of
the liver is very largely protected in the group administered ADMA + AA (H&E 100×), there is slight inflammation in a portal area
(arrow). C) Liver section of control group. There is no inflammation in portal areas and parenchyma (H&E 100×). PT: Portal area
(tract); CV: central vein; ADMA: asymmetric dimethylarginine; AA: ascorbic acid.

456

OKUYUCU et al. / Turk J Biol

Figure 2. Moderate inflammation in the portal area, piecemeal
necrosis (white arrow), and confluent necrosis (black arrow)
in the parenchyma are seen in the group administered ADMA
for 10 days (H&E 200×). PT: Portal area (tract); ADMA:
asymmetric dimethylarginine.
Table 3. Comparison of the groups with respect to histopathological parameters after 10 days of ADMA and AA
administration. The parameters showed that there was liver injury after administration of ADMA.
Groups

Control, median
(min–max)

ADMA, median
(min–max)

ADMA + AA,
median (min–max)

P-value

Interface hepatitis

0 (0–0)

0 (0–1)

0 (0–0)

0.040a,b

Confluent necrosis

0 (0–1)

1.5 (0–3)

1 (0–2)

0.001a

Focal necrosis

1 (0–1)

2 (0–3)

1.5 (1–2)

0.001a

Portal inflammation

1 (0–1)

1 (0–3)

1 (0–1)

0.030a

Histologic activity index

1 (0–3)

5 (0–10)

3.5 (2–5)

0.001a

Severity of hepatitis

1 (0–1)

2 (0–3)

1.5 (1–2)

0.003a

Fibrosis

0 (0–0)

0 (0–1)

0 (0–1)

>0.05c

Obtained by comparison between control and ADMA groups.
Obtained by comparison between ADMA and ADMA + AA groups.
c
Obtained by Kruskal–Wallis H test.
ADMA: asymmetric dimethylarginine; AA: ascorbic acid.
a

b

type 3), neuronal NOS (nNOS, type 1), and inflammatory
NOS (iNOS, type 2) (Tsutsui et al., 2009, 2010). As well
as NOS-mediated synthesis, NO is also generated from
proteins such as S-nitrosothiols, S-nitroproteins, and
nitrosyl hemoglobin (Kelm, 1999). Certain amounts of NO
are quite important for endothelial functions and tissue
homeostasis. Its insufficient secretion causes dysfunction
in the endothelium and various systems while excessive
levels lead to tissue deterioration. Excessive levels of NO
produced by iNOS form toxic peroxynitrite radicals by
reacting with superoxide radicals (Hierholzer et al., 1998;

Fan et al., 1999). Peroxynitrite, beside many other harmful
effects, causes reduction in DDAH activity and increased
levels of ADMA (Leiper et al., 2002).
NO is one of the essential regulators of intrahepatic
vascular tone and decreased production of NO results
in portal hypertension (Iwakiri et al., 2008; Sanyal et al.,
2008). NOS inhibitors such as caveolin-1 (Shah et al.,
1999), ADMA (Mookerjee et al., 2007b), and NOSTRIN
(Mookerjee et al., 2007c) play roles in the occurrence
of portal hypertension. Severity of portal hypertension
is correlated with levels of ADMA (Mookerjee et al.,
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2007b). Mookerjee et al. detected an elevation in plasma
and hepatic ADMA levels in cirrhosis and found that this
elevation was associated with decreased hepatic eNOS
activity, increased portal pressure, and increased mortality
rate (Mookerjee et al., 2007b). Martinez et al. generated
chronic liver failure by bile duct ligation in rats, and
they observed the rats for 6 weeks. ADMA levels were
analyzed to evaluate the endothelial dysfunction and were
seen to be higher after ligation (Garcia-Martinez et al.,
2015). In our study, ADMA administered to rats caused
a deterioration in hepatic perfusion and liver damage by
leading to inhibition of eNOS activity. ADMA also led to
secretion of various factors and tissue damage by causing
endothelial dysfunction.
Increased levels of ADMA that inhibit NO synthesis
were found to be associated with endothelial dysfunction,
vasoconstriction, peripheral artery disease, coronary artery
diseases, preeclampsia, hypertension, stroke, heart failure,
chronic kidney failure, portal hypertension observed in the
clinical picture of cirrhosis, diabetes mellitus, and insulin
resistance in the patients with essential hypertension
(Alacam et al., 2011; Sheen et al., 2014). It is known that
ADMA increases in hepatic diseases; however, it is still
controversial whether increased ADMA level is the reason
for or the result of hepatic deterioration. We administered
ADMA to rats to provide a contribution to these debates
and we detected that ADMA causes hepatic deterioration.
Our results demonstrate that ADMA is the reason for
hepatic deterioration.
ADMA is synthesized by PRMT1 (Tran et al., 2003;
Vallance and Leiper, 2004). ADMA, SDMA. and L-arginine
compete to be carried by CATs through membranes
(Forstermann et al., 1991; Hattori et al., 1999; Ferrigno
et al., 2015). CAT-2B is a low-capacity transporter and
demonstrates high affinity to cationic amino acids,
particularly ADMA (Closs et al., 1997). The liver takes up
the most amounts of ADMA from serum and metabolizes
it, mediated by particularly DDAH1 (Ferrigno et al., 2014).
It was detected in a study by Siroen et al. that patients
with preoperative liver transplantation had higher levels
ADMA when compared with healthy subjects. Plasma
ADMA levels decreased 1 day after transplantation in the
patients with either ALF or chronic liver failure. Plasma
ADMA levels were found higher at the onset of rejection
and the 14th and 28th days of transplantation in 85% of
the patients who had rejection as compared to those who
did not experience rejection. All these results demonstrate
that the liver is important in the clearance of ADMA,
that DDAH activity is preserved during transplantation
procedures, and that ADMA levels may provide data about
liver functions in the posttranslational period (Siroen et
al., 2004).
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Cardiovascular risk factors such as hyperglycemia
and hyperhomocysteinemia cause a reduction in DDAH
activity by ROS-mediated ways whereas antioxidants
lead to an elevation in DDAH activity (Nakagami et al.,
2009; Nakamura et al., 2009). Inflammatory genes cause
increased ADMA levels by activating PRMT and inhibiting
DDAH (Sydow and Munzel, 2003; Lee et al., 2005). ADMA
itself also causes increased levels of MDA, which is an
indicator of oxidative stress, while it leads to reduction in
the activities of antioxidant enzymes and DDAH (Jeremy
et al., 1999; Cerwinka et al., 2002). ADMA administered
to the rats in our study may have caused a reduction in
DDAH activity and consequently there may have been
excessive amounts of ADMA in the liver. This possibility
is not unlikely when the oxidative stress-increasing effect
of ADMA is considered (Alaçam et al., 2013). However,
antioxidant ascorbic acid administered to the rats did
not provide sufficient recovery of either biochemical
or histopathological parameters. These results make us
consider that the deteriorative effect of ADMA may result
from different factors other than oxidative stress.
Many pathways are accepted as being responsible for
the pathophysiology of acute and chronic liver diseases.
The ADMA/DDAH/NO pathway is also one of the
affected pathways (Mookerjee et al., 2007a). Increased
levels of ADMA observed in hepatic dysfunctions are due
to increased levels of protein breakdown or decreased
DDAH activity (Mookerjee et al., 2007b; Pilz et al.,
2015). The reduction in DDAH activity may originate
from local inflammation, from increased oxidative stress,
or directly from the reduction in the amount of DDAH
protein (Nijveldt et al., 2003b). In the study of Bal et al.,
hepatic injury was induced by administrating LPS/DGalN in rats. In the group administered LPS/D-GalN,
reduced DDAH activity and increased levels of arginine
and ADMA were encountered. When the rats were
administered metformin, DDAH activity increased while
levels of arginine and ADMA regressed to the levels of
control group. In the same study, a reduction was found
in the hepatic glutathione levels and increased prooxidant
activity was considered as the reason for this reduction.
It was reported that increased myeloperoxidase activity in
the liver tissue reveals inflammation and reduced DDAH
activity resulted from this inflammation (Bal et al., 2014).
Pilz et al. analyzed the correlation between Child–Pugh
and Model for End-Stage Liver Disease (MELD) scores
that indicate liver dysfunction and arginine metabolites.
Homoarginine, SDMA, and DAS (ADMA + SDMA) were
found correlated with only MELD score, whereas ADMA
was detected to be correlated with both Child–Pugh and
MELD scores. Mortality rate was found correlated with
ADMA, SDMA, and DAS values over median values
and homoarginine levels below median value. It was
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stated that ADMA is one of the indicators of hepatic
dysfunction and that ADMA is one of the responsible
factors for poor outcome in the patients with cirrhosis
(Pilz et al., 2015). In a study conducted in an intensive
care unit, baseline ADMA levels of the patients with liver
failure that developed due to high-dose administration of
acetaminophen at admission to the intensive care unit were
found higher than those of the control group. In the same
study, ADMA levels showed elevation in the anhepatic
phase during transplantation. Providing reperfusion of
the portal vein and hepatic artery reduced ADMA levels
and this reduction in ADMA levels continued in the
period following reperfusion. In the same study, a positive
correlation was detected between proinflammatory
mediators such as TNF-α, IL-1β, and IL-6 and ADMA
while the highest ADMA levels were encountered in
patients with the highest systemic inflammatory response
syndrome score (Mookerjee et al., 2007a). As can be seen,
prooxidant activity and inflammation that locally increased
in the liver tissue contributed to the liver injury caused by
ADMA. In our study, an elevation was also observed in
portal inflammation when ADMA was administered, and
it probably contributed to the injury induced by ADMA.
The suggested ADMA-multiorgan failure (MOF)
hypothesis states that ADMA plays an important role in
MOF (Lopez et al., 2004). Increased hepatic ADMA levels
lead to deterioration of hepatic perfusion and functions.
This deterioration causes an excessive elevation in serum
ADMA levels and results in further hepatic dysfunction
by a vicious circle. Increased ADMA levels cause not only
hepatic dysfunction but also lead to impaired functions of
other organs, and this elevation in ADMA levels is very
important in the pathophysiology of MOF (Harbrecht
et al., 2001). High levels of ADMA were encountered
in MOF that developed in patients with sepsis and that
accompanied hepatic dysfunction; it was an independent
prognostic predictor (Nijveldt et al., 2003b). Milewski et
al. found higher plasma and brain cortex ADMA levels
than those in the control group in rats with thioacetamideinduced acute liver failure. In the same study, a reduction
was encountered in brain and liver DDAH activity and

also in brain NOS activity in rats with acute liver failure
(Milewski et al., 2015). ADMA administered in our study
may have caused deterioration in other tissues by leading
to a reduction in NO levels. New studies may be conducted
to clarify this issue.
There are publications that suggest that plasma ADMA
levels may be reduced by pharmacotherapy and dialysis
(Beltowski and Kedra, 2006). High plasma levels of ADMA
have been successfully reduced using renin-angiotensin
system inhibitors (Yilmaz et al., 2007). Since ADMA (~202
Da) has a low molecular weight similar to urea (60 Da),
dialysis treatment appears to be a treatment selection to
reduce ADMA levels (Anderstam et al., 1997; Schmidt
et al., 1999). DDAH activity can be increased by several
signal pathways. GW4064, being an agonist of farnesoid
X receptor, causes increased DDAH1 gene expression
and a reduction in ADMA levels (Hu et al., 2006). The
effects of flavonoids and antioxidants on ADMA/DDAH
levels are currently being studied. In the study of Trocha
et al., a reduced hepatic ADMA level and an increased
DDAH activity were encountered when quercetin as a
flavonoid was administered in a low dosage (Trocha et al.,
2012). ADMA-reducing treatments may be an approach
in treatment of advanced-stage liver diseases. For this
purpose, ascorbic acid was administered as an antioxidant
in our study and it was tested whether it reduced the
harmful effects of ADMA. Ascorbic acid decreased in vivo
oxidative load and injury induced by ADMA thanks to
its antioxidant properties even if this reduction was not
significant. This may be due to an insufficient dosage of
ascorbic acid and lack of time. Ascorbic acid might be given
for more than 10 days and at higher dosages. We chose
the time and dosage for this study based on the literature.
(Alaçam et al., 2013; Okuyucu et al., 2015). Different doses
and durations may be tested in future studies.
In conclusion, occurrence of liver injury when rats
were administered ADMA indicates that ADMA is a factor
in the formation of liver injury. Insufficient recovery when
an antioxidant was administered makes us consider that
different factors besides prooxidant factors are effective in
the formation of liver injury.
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